tremelimumab (Imjudo)
Jump to navigation
Jump to search
Indications
- experimental agent for metastatic melanoma
- metastatic head & neck cancer PD-L1 negative[2]
- in combination with durvalumab for treatment of hepatocellular carcinoma[3]
Dosage
- once a month dosing (phase 2 trials)
- 15 mg/kg every 3 months selected for further clinical testing
- monotherapy or in combination with durvalumab
alone at 10 mg/kg intravenously every 4 weeks for 7 cycles then every 12 weeks for 2 cycles[2]
Adverse effects
Mechanism of action
- human IgG2 monoclonal antibody
- blocks cytotoxic T lymphocyte-associated antigen 4 (CTLA4)
- promotes T-cell activity
- does not deplete regulatory T cells[2]
More general terms
References
- ↑ Camacho LH et al. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol 2009 Mar 1; 27:1075. PMID: https://www.ncbi.nlm.nih.gov/pubmed/19139427
- ↑ 2.0 2.1 2.2 2.3 Fuerst ML with comments by Klil-Drori AJ Durvalumab Combo Slows PD-L1-neg Advanced Head and Neck Cancer. Increase in 'clinically relevant' overall survival, with manageable toxicity MedPage Today. ASCO Reading Room 05.03.2018 https://www.medpagetoday.com/reading-room/asco/immunotherapy/72666
Siu L, et al A randomized, open-label, multicenter, global phase 2 study of durvalumab (D), tremelimumab (T), or D plus T in patients with PD-L1 low/negative recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): CONDOR Int J Rad Oncol Biol Physics 2018; 100 (5): 1307. Not indexed in PubMed - ↑ 3.0 3.1 Leiser M FDA approves tremelimumab with durvalumab for advanced liver cancer. Helio. Oct 24, 2022 https://www.healio.com/news/hematology-oncology/20221024/fda-approves-tremelimumab-with-durvalumab-for-advanced-liver-cancer